Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Radoï L, Luce D. A review of risk factors for oral cavity cancer: the importance of a standardized case definition. Community Dent Oral Epidemiol. 2013;41(2):97–109. doi:10.1111/j.1600-0528.2012.00710.x22882534
   PubMed Web of Science ®Google Scholar
• Turati F, Garavello W, Tramacere I, et al. A meta-analysis of alcohol drinking and oral and pharyngeal cancers: results from subgroup analyses. Alcohol Alcohol. 2013;48(1):107–118. doi:10.1093/alcalc/ags10022949102
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–4559. doi:10.1200/JCO.2013.50.387024248688
   PubMed Web of Science ®Google Scholar
• Chindapasirt J. Mini-review sarcopenia in cancer patients. Asian Pac J Cancer Prev. 2015;16:8075–8077.26745041
   PubMedGoogle Scholar
• Reynolds P. Characteristics of ageing skeletal muscle. Physiother Theory Pract. 1991;7(3):157–162. doi:10.3109/09593989109106967
   Google Scholar
• Larsson L. Histochemical characteristics of human skeletal muscle during aging. Acta Physiol Scand. 1983;117(3):469–471. doi:10.1111/j.1748-1716.1983.tb00024.x6880808
   PubMedGoogle Scholar
• Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–635. doi:10.1016/S1470-2045(08)70153-018539529
   PubMed Web of Science ®Google Scholar
• Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol. 2017;71:26–33. doi:10.1016/j.oraloncology.2017.05.01228688687
   PubMed Web of Science ®Google Scholar
• Ganju RG, Morse R, Hoover A, et al. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019;137(2019):117–124. doi:10.1016/j.radonc.2019.04.02331085391
   PubMed Web of Science ®Google Scholar
• Grossberg AJ, Chamchod S, Fuller CD, et al. Association of body composition with survival and locoregional control of radiotherapy-treated head and neck squamous cell carcinoma. JAMA Oncol. 2016;2(6):782–789. doi:10.1001/jamaoncol.2015.633926891703
   PubMed Web of Science ®Google Scholar
• Peterson SJ, Mozer M. Differentiating sarcopenia and cachexia among patients with cancer. Nutr Clin Pract. 2017;32(1):30–39. doi:10.1177/088453361668035428124947
   PubMed Web of Science ®Google Scholar
• Jeejeebhoy KN. Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia: overlap of clinical features. Curr Opin Clin Nutr Metab Care. 2012;15(3):213–219. doi:10.1097/MCO.0b013e328352694f22450775
   PubMed Web of Science ®Google Scholar
• Lauretani F, Semba RD, Bandinelli S, et al. Carotenoids as protection against disability in older persons. Rejuvenation Res. 2008;11(3):557–563. doi:10.1089/rej.2007.058118593275
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.00322995477
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi:10.1016/S1470-2045(10)70218-721296615
   PubMed Web of Science ®Google Scholar
• Miyake M, Morizawa Y, Hori S, et al. Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. BMC Cancer. 2017;17(1):1–11.28049525
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–1547. doi:10.1200/JCO.2012.45.272223530101
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.24423208313
   PubMed Web of Science ®Google Scholar
• Rier HN, Jager A, Sleijfer S, et al. The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature. Oncologist. 2016;21(11):1396–1409. doi:10.1634/theoncologist.2016-006627412391
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. doi:10.1046/j.1365-2125.2003.02007.x14678335
   PubMed Web of Science ®Google Scholar
• Loong HH, Ma BBY, Leung SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):300–304. doi:10.1016/j.radonc.2011.12.02222300609
   PubMed Web of Science ®Google Scholar
• Hamauchi S, Yokota T, Onozawa Y, et al. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Jpn J Clin Oncol. 2015;45(12):1116–1121.26423341
   PubMed Web of Science ®Google Scholar
• Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non–small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124(3):606–616. doi:10.1002/cncr.3112829205286
   PubMed Web of Science ®Google Scholar
• Garg S, Yoo J, Winquist E. Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review. Support Care Cancer. 2010;18(6):667–677. doi:10.1007/s00520-009-0686-319582484
   PubMed Web of Science ®Google Scholar
• Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck. 2005;27(8):659–668. doi:10.1002/hed.2022115920748
   PubMed Web of Science ®Google Scholar
• Fietkau R, Riepl M, Kettner H, et al. Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Eur J Cancer. 1997;33(1):75–79. doi:10.1016/S0959-8049(96)00309-79071903
   PubMed Web of Science ®Google Scholar
• Chen HC, Leung SW, Wang CJ, et al. Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Radiother Oncol. 1997;43(1):75–79. doi:10.1016/S0167-8140(97)01921-X9165140
   PubMed Web of Science ®Google Scholar
• Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–307.e2. doi:10.1016/j.jamda.2019.12.01232033882
   PubMed Web of Science ®Google Scholar